Myomaker Bio Raises $43

OpenTrade

OpenTrade provides an institutional grade platform for yield products designed for fintechs and institutional investors across Web2 and Web3 ecosystems. Our offerings combines a technology platform with legal and operational frameworks and services that together support safe, compliant, and scalable yield products for the next generation of financial services & markets.

CellCentric

Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally. p300/CBP are twin (paralogue) acetyl transferases, and importantly, gene activating proteins that are known to play an important role in the progression of certain cancers. CellCentric’s pioneering drug is in Phase I/II clinical trials to evaluate its effectiveness to treat specific solid tumours, as well as haematological malignancies (blood cancers). These represent major clinical unmet needs, delivering a new therapy for people with cancer, who otherwise have few alternatives.

OnRe

OnRe is licensed to deploy digital assets as insurance collateral, connecting onchain capital to real-world reinsurance risk. It delivers competitive, uncorrelated institutional-grade returns for investors and DeFi participants through ONyc, its yield-bearing asset. ONyc combines RWA-backed underwriting with crypto-native strategies to create liquid, composable collateral for DeFi and position stablecoins as credible funding tools for real-world assets.

ecodetect

AI-driven marine detection, in harmony with nature

NunaBio Limited

As a next-generation CDMO, NunaBio delivers universal, cell-free DNA solutions in any format, for a range of applications from therapies to advanced materials. Disposable, SaaS-controlled hardware units enable DNA production from research to commercial scale in a fraction of the space required by traditional methods. This allows researchers, developers, and manufacturers to move seamlessly from discovery to clinical development without delays, compromises, or safety risks.